Diffuse large B-cell lymphoma · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | — | — | 24 | R 52 272 PFS proxy | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~5.2 mo | — | ~1 | — | 3 |
2 of 2 regimens shown